[SCHEDULE 13D/A] Design Therapeutics, Inc. Amended Major Shareholder Report

Rhea-AI Filing Summary

SR One Capital Fund I Aggregator, SR One Capital Partners I, SR One Capital Management and Simeon George filed an amended beneficial ownership report for Design Therapeutics, Inc. common stock. Aggregator, Partners I and Parent each report beneficial ownership of 6,526,476 shares, representing 10.6% of the outstanding common stock.

Dr. Simeon George reports beneficial ownership of 6,607,892 shares, or 10.7% of the class, including 81,416 shares over which he has sole voting and dispositive power and 6,526,476 shares over which he shares voting and dispositive power. The filing states that their percentage ownership decreased by more than 1% because the issuer’s outstanding common stock increased to 61,672,279 shares as of March 2, 2026, and notes that none of the reporting persons has traded the stock in the last 60 days.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

Design Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

Sasha Keough
c/o SR One Capital Management, LP, 929 Main Street, Suite 200
Redwood City, CA, 94063
(410) 800-7503

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

03/09/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

SR One Capital Fund I Aggregator, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,526,476.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,526,476.00

11

Aggregate amount beneficially owned by each reporting person

6,526,476.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

10.6 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

SR One Capital Partners I, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,526,476.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,526,476.00

11

Aggregate amount beneficially owned by each reporting person

6,526,476.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

10.6 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

SR One Capital Management, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,526,476.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,526,476.00

11

Aggregate amount beneficially owned by each reporting person

6,526,476.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

10.6 %

14

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Simeon George

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 81,416.00
8	Shared Voting Power 6,526,476.00
9	Sole Dispositive Power 81,416.00
10	Shared Dispositive Power 6,526,476.00

11

Aggregate amount beneficially owned by each reporting person

6,607,892.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

10.7 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value per share
(b)	Name of Issuer: Design Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 6005 Hidden Valley Road, Suite 110, Carlsbad, CALIFORNIA , 92011.
Item 1 Comment: This Amendment No. 2 ("Amendment No. 2") to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on April 9, 2021 (the "Schedule 13D") and Amendment No. 1 thereto filed on December 22, 2022 ("Amendment No. 1") relating to the Common Stock of the Issuer. Certain terms used but not defined in this Amendment No. 2 have the meanings assigned thereto in the Schedule 13D (and Amendment No. 1 thereto). Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported on the Schedule 13D (and Amendment No. 1 thereto). This Amendment No. 2 is being filed to report that the beneficial ownership of Common Stock by the Reporting Persons (as defined below) has decreased by more than 1% as a result of an increase in the number of Common Stock outstanding.
Item 2.	Identity and Background
(a)	SR One Capital Fund I Aggregator, LP ("Aggregator"); SR One Capital Partners I, LP ("Partners I"); SR One Capital Management, LLC ("Parent"); and Simeon George, M.D. ("Dr. George"). Aggregator is directly controlled by its general partner, Partners I. Partners I is directly controlled by its general partner, Parent, and Dr. George controls Parent. Accordingly, each of Partners I, Parent and Dr. George may be deemed to have voting and dispositive power with respect to the Shares owned by Aggregator. The persons named in this Item 2 are referred to individually herein as a "Reporting Person" and collectively as the "Reporting Persons."
(b)	The address of each Reporting Person for purposes of this filing is c/o SR One Capital Management, LP, 929 Main Street, Suite 200, Redwood City, CA 94063.
(c)	The principal business of Aggregator is to invest in and assist growth-oriented businesses. The principal business of Partners I is to act as the sole general partner of Aggregator. The principal business of Parent is to act as the sole general partner of Partners I and a number of affiliated partnerships with similar businesses. The principal business of Dr. George is to manage Parent.
(d)	During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(e)	During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	Aggregator and Partners I are limited partnerships organized under the laws of the State of Delaware. Parent is a limited liability company organized under the laws of the State of Delaware. Dr. George is a United States citizen.
Item 3.	Source and Amount of Funds or Other Consideration
	Not applicable.
Item 4.	Purpose of Transaction
	Not applicable.
Item 5.	Interest in Securities of the Issuer
(a)	The percentage of outstanding shares of Common Stock which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based on 61,672,279 shares of Common Stock reported by the Issuer to be outstanding as of March 2, 2026, on the Issuer's Form 10-K filed with the Securities Exchange Commission on March 9, 2026.
(b)	Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.
(c)	None of the Reporting Persons has effected any transaction in shares of Common Stock during the last 60 days.
(d)	No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Common Stock beneficially owned by any of the Reporting Persons.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not applicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1 - Agreement regarding filing of joint Schedule 13D. Exhibit 2 - Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SR One Capital Fund I Aggregator, LP

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	03/11/2026

SR One Capital Partners I, LP

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	03/11/2026

SR One Capital Management, LLC

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	03/11/2026

Simeon George

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	03/11/2026

Comments accompanying signature:

This Amendment No. 2 to Schedule 13D was executed by Sasha Keough on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.